Skip to main content
Log in

Ocriplasmin provides additional benefit, says IQWiG

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. where the vitreous body of the eye remains partly stuck to the retina after a vitreous detachment, resulting in distorted/blurred vision

Reference

  • IQWiG. Ocriplasmin: indication of major added benefit for certain patients. Media Release : 1 Aug 2013. Available from: URL: http://www.iqwig.de

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ocriplasmin provides additional benefit, says IQWiG. PharmacoEcon Outcomes News 684, 11 (2013). https://doi.org/10.1007/s40274-013-0626-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0626-9

Navigation